Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)

Background: Androgen deprivation therapy (ADT) for prostate cancer with luteinizing hormone-releasing hormone (LHRH) agonists can be improved. Objective: To assess safety, the frequency and severity of hot flushes (HFs), bone health, and antitumor effects of high-dose estetrol (HDE4) when combined w...

Full description

Bibliographic Details
Main Authors: Herjan J.T. Coelingh Bennink, Jeroen A. van Moorselaar, E. David Crawford, Erik P.M. Roos, Diederik M. Somford, Ton A. Roeleveld, Tjard D. de Haan, Harm H.E. van Melick, Yacov Reisman, Yvette Zimmerman, Gonnie van Osta, Jan Krijgh, Neal D. Shore, Fred Saad, Andrew V. Schally, Frans M.J. Debruyne
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:European Urology Open Science
Subjects:
Androgen deprivation therapy
Bone
Cardiovascular safety
Antitumor efficacy
Estetrol
Hot flushes
Online Access:http://www.sciencedirect.com/science/article/pii/S2666168321000793

Internet

http://www.sciencedirect.com/science/article/pii/S2666168321000793

Similar Items